A method for determining the concentration of FG020326 in mice plasma by RP-HPLC

Chinese Pharmacological Bulletin

Volumn 23, Issue 1, 2007, Pages 131-134

  Dai, Chun Ling ^a,b   Li, Su ^a,b   Liang, Yong Ju ^a,b   Liao, Hai ^a,b   Deng, Wen Jing ^a,b   Yan, Lin ^a,b   Fu, Li Wu ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

FG020326; MDR; Pharmacokinetics; RP HPLC

Indexed keywords

FG 020326; IMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FREEZE THAWING; MOUSE; NONHUMAN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TEMPERATURE SENSITIVITY;

EID: 34247468069     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Chen L M, Liang YJ, Fu L W, et al. Screening novel, potent multidrug-resistant modulators from imidazole derivatives[J]. Oncol Res, 2004,14(7-8): 355-62.
2. Chen L M, Gu L Q, Fu L W, et al. Reversal of P-gp mediated multidrug resistance in vitro and in vivo by FG020318 [J]. J. Pharm Pharmacol, 2004,56(8): 1061-6.
3. Wang X W, Chen L M, Fu L W, et al. Enhancement of FG020326 on sensitivity of MCF-7/ADR cells to taxotere via enhancing activation of Caspase-8 and Caspase-3[J]. Chin J Cancer, 2004,23(11s): 1379-85.
4. Dai C L, Fu L W. The development of the reversal of the tumor multidrug resistance[J]. Clin Pharmacol Bull, 2005,21(5): 513 -8.
5. Bates S E, Bakke S, Kang M, et al. A phase I/II study of incisional vinblastine with the P-glycoprotein antagonist valspodar (PSC833) in renal cell carcinoma[J]. Clin Cancer Res, 2004,10 (14): 4724-33.
6. Minderman H, O'Loughlin K L, Pendyala L, et al. VX-710(biricodar) increasea drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein[J]. Clin Cancer Res, 2004,10(5): 1826-34.
7. Sandler A, Gordon M, De Alwis D P, et al. De A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy[J]. Clin Cancer Res, 2004,10(10): 3265-72.
8. Newman M J, Rodarte J C, Benbatoul K D, et al. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance[J]. Cancer Res, 2000,60(11): 2964-72.
9. Guns E S, Denyssevych T, Dixon R, et al. Drug interaction studies between paclitaxel (Taxol) and OC144-093 - a new modulator of MDR in cancer chemotherapy[J]. Eur J Drug Metab Pharmacokinet, 2002,27(2): 119-26.